HPV Testing Management Important For Women

Many people knock on the consultation room door after seeing the phrase "high-risk HPV positive" on a health checkup result. "I don't even know what HPV is, and now it says high-risk — could it be cancer?" is usually the first anxious question. To say the conclusion first, HPV is a virus common enough that any sexually active woman may be exposed to it at least once, and a positive result alone does not turn into cancer. However, knowing "which type it is" and "how to follow up going forward" is an entirely different matter. Today we will work through, step by step, why the HPV test matters and what to do after receiving the result.

HPV (human papillomavirus) is not a single virus but a huge virus group of more than 200 types. Of these, about 40 infect the genital mucosa, and in clinical practice these are further divided into two branches. By the World Health Organization (WHO, 2020) standard, there is the high-risk group, which can cause cervical cancer, and the low-risk group, mainly associated with benign lesions such as genital warts (condyloma).

The reason for managing the high-risk group separately is clear. According to the American Society for Colposcopy and Cervical Pathology (ASCCP) and the American Cancer Society (ACS, 2020), most cervical cancer is reported to be associated with persistent infection by high-risk types, especially type 16 and type 18. In other words, even for the same "positive," the intensity of follow-up differs depending on which HPV number you carry. In the consultation room, a single type number written on the test sheet can completely change a patient's next screening schedule and the weight on her mind.

Let us first clear up the most common misunderstanding. Being infected with HPV does not lead straight to cervical cancer. The medical literature reports that in women with a healthy immune system, a large proportion of HPV infections clear naturally within 1 to 2 years without any particular lesion. This is the process by which our immune cells clear the virus on their own, and this tendency toward natural clearance is especially marked in younger age groups.

What becomes a problem is persistent infection. When the same high-risk type evades immune surveillance and remains for several years, cervical cells can progress to a precancerous stage of gradual change. This process can be summarized as follows.

• Transient infection: Most clear naturally through immunity within 1 to 2 years, and in many cases no additional treatment is needed.
• Persistent infection: This is when the same high-risk type is repeatedly detected, a signal that close follow-up is needed.
• Precancerous lesion (cervical intraepithelial neoplasia, CIN): A stage where cell change has begun; depending on the grade, follow-up or treatment is considered.

The key is not "whether you were infected" but "how long, and which type, lingers." So rather than a single positive, retesting and follow-up spaced over time give more important information.

The starting point of HPV management is accurate testing. Cervical screening is largely made up of two axes. One is cytology (the cervical cytology test, often called the Pap test), which directly looks at changes in cell shape, and the other is the HPV test, which checks for the presence of the high-risk virus itself. Because the two tests look at different targets, they complement each other.

The American Cancer Society (ACS, 2020) and ASCCP have revised their guidelines toward recommending screening centered on the high-risk HPV test. According to the reported recommendations, in certain age groups they advise performing HPV testing alone or co-testing with cytology at set intervals, and Korea's national cervical cancer screening also operates a regular screening system for women of a certain age and older. Because the screening cycle and items differ according to individual age, past results, and risk factors, we recommend referring together to the how often you should get cervical cancer screening item and a consultation to find the schedule that fits you.

More important than the test is the management after the result. A high-risk HPV positive result itself is "the start of follow-up," not "the end of diagnosis." In the consultation room, we usually explain along the following flow.

1. Confirm the type: We set the intensity of follow-up according to whether it is a high-risk type such as 16 or 18.
2. Interpret together with the cytology result: We look at whether cell change accompanies it.
3. Precise testing if needed: We confirm whether there is a precancerous lesion with colposcopy or biopsy.
4. Regular retesting: To confirm whether natural clearance has occurred, we conduct retesting spaced over time.

In particular, when the cytology also shows a change of ambiguous meaning, separate interpretation is needed. We have explained this part in more detail in the article on ASCUS and cervical dysplasia on Pap tests, so if you see an unfamiliar abbreviation on your result sheet, reading it together may help. In clinical experience, simply understanding the meaning of the result accurately reduces a considerable part of unnecessary anxiety.

HPV management does not end with testing and follow-up alone. The picture is completed only when prevention, one axis, goes along with it. The primary prevention whose effect is clearest is the vaccine. The 9-valent vaccine currently in use (Gardasil 9) is approved by the U.S. FDA for vaccination from ages 9 to 45, and it is reported that the earlier it is given before infection, the higher the preventive effect. The U.S. Advisory Committee on Immunization Practices (ACIP) recommendation advises completing vaccination during adolescence as the standard, while adults aged 27 to 45 are advised to decide on vaccination through consultation with a medical professional.

Even if you are already infected with one type, the vaccine is not meaningless, because the vaccine also prevents other types you have not yet been exposed to. However, since the expected effect can have individual differences according to one's infection history and age, it is better to confirm in care whether you can get the HPV vaccine even after already being infected.

The second axis is immune management in daily life. As we saw earlier, the natural clearance of HPV is a process that leans on immunity, so basic health habits such as sufficient sleep, balanced nutrition, not smoking, and stress control become a solid foundation for follow-up management. We always end up emphasizing in the consultation room that it is not a flashy secret but a steady daily routine that makes immunity your ally.

Because HPV is transmitted through sexual contact, a partner can also be a carrier. Men often have no symptoms, but managing it together and considering vaccination is a way to reduce the risk of reinfection and to be considerate of each other. That said, dwelling on "who passed it on" has little medical meaning either, because it is so common and has such a long latency that pinpointing the time of infection is difficult.

Above all, the important thing is not to skip regular screening. The World Health Organization (WHO, 2020) regards cervical cancer as a disease that can be sufficiently reduced through three axes — vaccination, regular screening, and early treatment at the precancerous stage — and has presented a global elimination strategy. The fact that HPV is common is not a reason for fear; rather, it also means that a well-paved path of testing and prevention is already in place.

Rather than lingering with the result sheet in an anxious frame of mind, it is far more comfortable to clearly know what your type is and what to do next. Regular checking of cervical health is the basis of women's health care, and if you would like to design testing and management together, at HPV and cervical cancer focused care you can receive guidance on a screening and follow-up plan that fits you.

Get a consultation on the HPV testing and management plan that fits you

Written by: Lee Dong-hee Director · OB-GYN specialist · View medical staff profile

First published September 23, 2025 · Last reviewed May 30, 2026

References: WHO Global Strategy to Accelerate the Elimination of Cervical Cancer (2020), ASCCP and American Cancer Society Cervical Cancer Screening Guidelines (2020), U.S. FDA Gardasil 9 Prescribing Information (2020), U.S. CDC ACIP HPV Vaccination Recommendations (2019)

This article is intended to provide general health information and does not replace individual diagnosis or treatment. If you have symptoms, please consult through an examination.